Sax Paul相关文献与解析，生知库 | 链接生命科学的每一步

Real-world effectiveness of early remdesivir in reducing mortality among vulnerable patients hospitalized for COVID-19: Evidence for clinical pharmacists and inpatient care providers

早期使用瑞德西韦降低新冠肺炎住院脆弱患者死亡率的真实世界疗效：为临床药师和住院护理人员提供的证据

期刊:American Journal of Health-System Pharmacy

影响因子:2.3

doi:10.1093/ajhp/zxag037

Loubet, Paul; Chandak, Aastha; Spivey, Susan; Doi, Yohei; Amin, Alpesh N; Ahuja, Neera; Müller, Veronika; Sax, Paul E

Clinical Consequences of Delaying Implementation of Long-Acting Antiretroviral Therapy for People With HIV and Persistent Viremia in the United States

美国艾滋病毒感染且持续病毒血症患者延迟实施长效抗逆转录病毒疗法的临床后果

期刊:Clinical Infectious Diseases

影响因子:

doi:10.1093/cid/ciaf428

Pei, Pamela P; Jones, Michelle; Hu, Ruitian; Chen, Wanyi; Sax, Paul E; Pandya, Ankur; Gandhi, Monica; Eron, Joseph J; Currier, Judith S; Wilkin, Timothy J; Reddy, Krishna P; Qoshe, Livia; Hyle, Emily P; Freedberg, Kenneth A

The clinical and economic impact of genotypic resistance testing for people diagnosed with persistent virological non-suppression on tenofovir-lamivudine-dolutegravir in South Africa: a modelling study

在南非，对接受替诺福韦-拉米夫定-多替拉韦治疗后持续病毒学抑制的患者进行基因型耐药性检测的临床和经济影响：一项建模研究

期刊:Lancet HIV

影响因子:13

doi:10.1016/S2352-3018(25)00164-X

Hyle, Emily P; Bekker, Linda-Gail; McCluskey, Suzanne M; Chen, Wanyi; Sax, Paul E; Moosa, Mahomed-Yunus; Machoko, Munashe; Bangs, Audrey; Steegen, Kim; Siedner, Mark J; van de Vijver, David A M C; Resch, Stephen C; Neilan, Anne M; Phillips, Andrew; Walensky, Rochelle P; Lessells, Richard J; Weinstein, Milton C; Dugdale, Caitlin M; Wood, Robin; Freedberg, Kenneth A

微生物学

发表日期：2025

文献求助收藏

Lower Mortality Risk Associated With Remdesivir + Dexamethasone Versus Dexamethasone Alone for the Treatment of Patients Hospitalized for COVID-19

对于因新冠肺炎住院的患者，瑞德西韦联合地塞米松治疗较单独使用地塞米松治疗具有更低的死亡风险。

期刊:Clinical Infectious Diseases

影响因子:7.3

doi:10.1093/cid/ciae477

Mozaffari, Essy; Chandak, Aastha; Gottlieb, Robert L; Chima-Melton, Chidinma; Berry, Mark; Oppelt, Thomas; Okulicz, Jason F; Amin, Alpesh N; Welte, Tobias; Sax, Paul E; Kalil, Andre C

A Systematic Review and Meta-analysis of the Effectiveness of Remdesivir to Treat SARS-CoV-2 in Hospitalized Patients: Have the Guidelines Evolved With the Evidence?

瑞德西韦治疗 SARS-CoV-2 住院患者疗效的系统评价和荟萃分析：指南是否随着证据的更新而发展？

期刊:Clinical Infectious Diseases

影响因子:7.3

doi:10.1093/cid/ciaf111

Bartoletti, Michele; Mozaffari, Essy; Amin, Alpesh N; Doi, Yohei; Loubet, Paul; Rivera, Christina G; Roshon, Michael; Rawal, Aaditya; Kaiser, Emily; Vutcovici Nicolae, Maria; Fu, Shuai; Oppelt, Thomas F; Chiang, Mel; Sax, Paul E; Kalil, Andre C

SARS-CoV-2

发表日期：2025

文献求助收藏

Intact and Defective HIV Provirus Changes During Antiretroviral Therapy in People Treated During Acute or Chronic HIV Infection or as HIV Controllers

在接受抗逆转录病毒治疗的急性或慢性 HIV 感染者或 HIV 控制者中，完整型和缺陷型 HIV 前病毒在治疗期间的变化

期刊:Open Forum Infectious Diseases

影响因子:3.8

doi:10.1093/ofid/ofaf568

Gandhi, Rajesh T; Cyktor, Joshua C; Bosch, Ronald J; Mar, Hanna; Laird, Gregory M; Martin, Albine; Riddler, Sharon A; Sax, Paul E; Li, Jonathan Z; McMahon, Deborah K; Mellors, John W; Eron, Joseph J

Melanocortin-4 Receptor Gene Variants and Weight Change Following Switch to Integrase Inhibitor-Based Antiretroviral Therapy

黑皮质素-4受体基因变异与改用整合酶抑制剂类抗逆转录病毒疗法后的体重变化

期刊:Open Forum Infectious Diseases

影响因子:3.8

doi:10.1093/ofid/ofaf696

Hulgan, Todd; Erlandson, Kristine M; Bradford, Yuki; Tassiopoulos, Katherine; Wu, Kunling; Bares, Sara H; Brown, Todd T; Lake, Jordan E; Leonard, Michael; McComsey, Grace A; Ritchie, Marylyn D; Sax, Paul E; Koethe, John R; Haas, David W

Efficacy of bictegravir/emtricitabine/tenofovir alafenamide versus dolutegravir-based three-drug regimens in people with HIV with varying adherence to antiretroviral therapy

在不同抗逆转录病毒治疗依从性的HIV感染者中，比克替拉韦/恩曲他滨/替诺福韦艾拉酚胺三药方案与基于多替拉韦的三药方案的疗效比较

期刊:Journal of Antimicrobial Chemotherapy

影响因子:3.6

doi:10.1093/jac/dkae407

Andreatta, Kristen; Sax, Paul E; Wohl, David; D'Antoni, Michelle L; Liu, Hui; Hindman, Jason T; Callebaut, Christian

Costs associated with increasing numbers of Medicare beneficiaries with HIV aged 65 years and older from 2026 to 2035

2026年至2035年，65岁及以上感染艾滋病毒的联邦医疗保险受益人数量增加所带来的相关成本

期刊:

影响因子:

doi:10.64898/2025.12.19.25342703

Hyle, Emily P; Ang, Luke; Luu, Grace; Kasaie, Parastu; Dai, Dannie; Koiso, Satoshi; Phelan, Jessica; Ebem, Florence; Duggan, Ciara; Humes, Elizabeth; Sax, Paul E; Gerace, Lucas; Giardina, John; Orav, E John; Neilan, Anne M; Pandya, Ankur; Figueroa, Jose F; Althoff, Keri N; Freedberg, Kenneth A

Protocols for Randomized Controlled Trials: Advancing Transparency in Infectious Diseases

随机对照试验方案：提升传染病领域的透明度

Real-world effectiveness of early remdesivir in reducing mortality among vulnerable patients hospitalized for COVID-19: Evidence for clinical pharmacists and inpatient care providers

早期使用瑞德西韦降低新冠肺炎住院脆弱患者死亡率的真实世界疗效：为临床药师和住院护理人员提供的证据

Clinical Consequences of Delaying Implementation of Long-Acting Antiretroviral Therapy for People With HIV and Persistent Viremia in the United States

美国艾滋病毒感染且持续病毒血症患者延迟实施长效抗逆转录病毒疗法的临床后果

The clinical and economic impact of genotypic resistance testing for people diagnosed with persistent virological non-suppression on tenofovir-lamivudine-dolutegravir in South Africa: a modelling study

在南非，对接受替诺福韦-拉米夫定-多替拉韦治疗后持续病毒学抑制的患者进行基因型耐药性检测的临床和经济影响：一项建模研究

Lower Mortality Risk Associated With Remdesivir + Dexamethasone Versus Dexamethasone Alone for the Treatment of Patients Hospitalized for COVID-19

对于因新冠肺炎住院的患者，瑞德西韦联合地塞米松治疗较单独使用地塞米松治疗具有更低的死亡风险。

A Systematic Review and Meta-analysis of the Effectiveness of Remdesivir to Treat SARS-CoV-2 in Hospitalized Patients: Have the Guidelines Evolved With the Evidence?

瑞德西韦治疗 SARS-CoV-2 住院患者疗效的系统评价和荟萃分析：指南是否随着证据的更新而发展？

Intact and Defective HIV Provirus Changes During Antiretroviral Therapy in People Treated During Acute or Chronic HIV Infection or as HIV Controllers

在接受抗逆转录病毒治疗的急性或慢性 HIV 感染者或 HIV 控制者中，完整型和缺陷型 HIV 前病毒在治疗期间的变化

Melanocortin-4 Receptor Gene Variants and Weight Change Following Switch to Integrase Inhibitor-Based Antiretroviral Therapy

黑皮质素-4受体基因变异与改用整合酶抑制剂类抗逆转录病毒疗法后的体重变化

Efficacy of bictegravir/emtricitabine/tenofovir alafenamide versus dolutegravir-based three-drug regimens in people with HIV with varying adherence to antiretroviral therapy

在不同抗逆转录病毒治疗依从性的HIV感染者中，比克替拉韦/恩曲他滨/替诺福韦艾拉酚胺三药方案与基于多替拉韦的三药方案的疗效比较

Costs associated with increasing numbers of Medicare beneficiaries with HIV aged 65 years and older from 2026 to 2035

2026年至2035年，65岁及以上感染艾滋病毒的联邦医疗保险受益人数量增加所带来的相关成本